Immuno-oncology treatments mobilize patient’s immune system to fight tumor cells. One of the approaches recently at the forefront of this therapy are chimeric antigen receptor (CAR)-T cells as a successful treatment modality for patients with leukemia or lymphoma. Immuno-oncology treatments have been approved by FDA in a variety of solid and hematological malignancies. A key advantage of using immuno-oncology therapy is the patient’s ability to fight recurrence more effectively.
With more than a decade of clients being served with CAR-T, TCR, TIL, and MSC manufacturing projects, Catalent is positioned to be your partner for commercial success. We are also at the forefront of continuous innovation in process development and optimizing the manufacturability of the new Natural Killer (NK) therapies. Catalent’s state-of-the-art Manufacturing by Design (MbD) methodology helps overcome many challenges associated with immune cell manufacturing. Our CGMP facilities across US and Europe are both regulated per FDA/EMA guidelines and deliver high-quality standards and process efficiency at production scale.
Almost all cell therapies in development or commercialization today target life threatening diseases, which severely impact the quality of life of the patient and their families. At Catalent, we employ a patient-first philosophy and share a commitment to rare disease patients and their future treatments.